Saturday, 08 August 2020

J&J puts all Chinese units under single local chairman

29 August 2013 | News | By BioSpectrum Bureau

Mr Jesse Wu – The new chairman of Johnson & Johnson, China, will oversee all three Chinese J&J  businesses units

Mr Jesse Wu – The new chairman of Johnson & Johnson, China, will oversee all three Chinese J&J businesses units

Singapore: The business heads of Johnson & Johnson's (J&J) three Chinese operations would report to one local chairman from next month. This move has been made by the firm in an effort to increase sales and centralize corporate oversight. The three Chinese operations have been reporting to separate business heads in the US.

Mr Jesse Wu, the worldwide chairman of J&J's consumer business, will become chairman of J&J China and would report directly to company chairman and chief executive Mr Alex Gorsky. Mr Wu will oversee an operation that includes 9,000 employees in China and $2.5 billion in sales last year.

Each of the three China units will still be responsible for determining its own business strategies. Mr Lynn Pendergrass, co-senior vice president, Hewlett-Packard, will join J&J, taking over Mr Wu's job as head of the firms's global consumer business.

Mr Ernie Knewitz, spokesman, J&J, said that the changes in China will help increase sales and add oversight to the "whole enterprise". He added, "Now it is all segmented like the rest of the world. You report through steps to the worldwide chairman of your unit. It definitely adds additional, and centralized, oversight for our whole enterprise in China, but the emphasis is on growing our business."

Mr Knewitz highlighted that J&J created a similar reporting structure in Vietnam last year and has been considering it for China over the past year in hopes of boosting profitability.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls